Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple undisclosed diseases.
The partnership will leverage Alloy’s proprietary AntiClastic™ antisense oligonucleotide (ASO) platform, a technology designed to overcome longstanding challenges in antisense drug development. Under the terms of the agreement, Alloy will receive an upfront payment and is eligible for additional milestone payments, as well as tiered royalties on any resulting commercial products.
Antisense therapies are designed to target RNA, enabling the modulation of gene expression at a fundamental biological level. While the approach holds significant promise, its clinical success has historically been limited by issues such as insufficient biodistribution, reduced potency, and safety concerns. Alloy’s AntiClastic platform aims to address these challenges by enhancing the delivery and effectiveness of antisense molecules within cells.
The platform incorporates novel oligonucleotide designs and a proprietary spatial configuration that improves the ability of therapeutic molecules to reach their intended RNA targets. This approach is also intended to reduce inflammatory responses and increase the therapeutic index, ultimately making treatments safer and more effective. According to the company, early data suggests that AntiClastic-based candidates may demonstrate significantly greater potency compared to traditional antisense formats.
Through the collaboration, Biogen will apply the AntiClastic platform to its research programs, drawing on its extensive experience in developing innovative medicines, particularly in neuroscience and rare diseases. The agreement reflects Biogen’s continued focus on exploring new scientific approaches to address complex conditions with unmet medical needs.
Alloy Therapeutics, known for its ecosystem-driven model, provides drug discovery platforms and technologies to partners across the biopharmaceutical industry. The company integrates advanced computational tools and artificial intelligence to accelerate the design and optimization of therapeutic candidates.
Company executives from both organizations emphasized the strategic importance of the collaboration. Alloy highlighted Biogen’s track record in translating cutting-edge research into clinical therapies, while Biogen underscored the value of accessing innovative technologies to expand its research capabilities.
The collaboration also builds on an existing relationship between the two companies, signaling a deepening partnership aimed at unlocking the full potential of antisense therapeutics. By combining Alloy’s discovery technologies with Biogen’s development expertise, the companies aim to accelerate the creation of new treatments that could significantly impact patient outcomes.
As the pharmaceutical industry continues to invest in genetic medicines, partnerships like this underscore the growing importance of RNA-targeting approaches in the next wave of drug innovation.